EasyBlog

This is some blog description about this site

COPENHAGEN, MAY 16, 2016 – AntibioTx and the Train2Target consortium, comprising leading academic groups and SME’s in the antimicrobial space, has been awarded a Horizon2020 grant to fund research and development. The grant will focus on antimicrobial resistance and in particular how to harness the challenges of the increasing problem with antibiotic resistance. Through the grant, AntibioTx will offer a PhD-position to a top-talented microbiologist who is passionate about the development of new antibacterial medicines.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, APRIL 07, 2016 – AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials. 

Professor Mylonakis is an expert in molecular biology, biostatistics, microbial and pathogenesis, which he often combines with a pragmatic problem-solving approach such as developing methods and strategies against antimicrobial resistance.

Professor Mylonakis is currently chief of the Infectious Diseases Division and Dean’s Professor of Medicine at the Warren Alpert Medical School of Brown. He has published more than 200 peer-reviewed scientific articles edited five books and has been on the editorial board of 10 scientific and peer-reviewed journals. 
Mylonakis has received several awards for his research, counting awards from the American Society for Microbiology and the Infectious Disease Society of America.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, MARCH 22, 2016 – AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed by a 28-day recovery period to ensure no detectable genotoxicity.

The study was conducted by researchers at the In-Life Testing Facility at Sinclair Research Center, LLC - located in Missouri, USA. Sinclair Research is specialized in preclinical studies and has broad experience in applied human and veterinary models.

Dr. Morten Sommer, CSO of AntibioTx, commented: “We are pleased about the outcome of the minipig study which supports further development of ATx201”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, OCTOBER 26, 2015 - AntibioTx has been rewarded grant funding from The Innovation Fund Denmark to further develop a candidate developed on the basis of extensive compound screening models. The candidate is being developed for microbiome-related disorders in atopic dermatitis and the grant funding will be used to conduct IND-enabling safety studies as well as clinical Phase 1 and Phase 2 studies in patients suffering from atopic dermatitis.

Rasmus Toft-Kehler, CEO of AntibioTx, commented; “The reward of this grant enables AntibioTx to take candidates identified through our screening efforts into the clinic. This denotes a key milestone for a biotech company and allows us to verify the pre-clinical profile of our candidate as a new treatment alternative for atopic dermatitis patients. We are grateful for the support and trust from the Innovation Fund Denmark and look forward to initiating the studies”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, AUGUST 12, 2013 - AntibioTx has been rewarded a nondilutive grant from The Advanced Technology Foundation to discover and develop novel medicine on the basis of an advanced screening approach. The grant was rewarded to support lead identification and in vivo proof-of-concept studies.

Rasmus Toft-Kehler, CEO of AntibioTx, commented: “The support from The Advanced Technology Foundation allows us to pursue our dream of building the basis for a sustainable pharmaceutical company with a focus on developing novel treatments for patients with a significant unmet medical need” to which Dr. Morten Sommer, CSO of AntibioTx, further added: ”We are very excited to receive this funding because it really allows us to test the screening concept to discover new medicines for a variety of microbial diseases”.

The grant funding supports in vitro and in vivo work over a three-year period with the objective to identify and validate one or more novel candidates for further preclinical development.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News